Paul Marston is counsel at Hughes Hubbard & Reed’s office in Tokyo. Paul focuses his practice on large-scale corporate transactions, including M&A and collaboration, development and licensing agreements in technology, pharmaceuticals, food products and other industries. In addition, Paul served as in-house counsel to a subsidiary of a large Japanese trading company, where he was responsible for managing complex litigation relating to the Macondo oil spill in the Gulf of Mexico. He also has worked in-house at SoftBank Group Corp.
Publications and Speaking Engagements
Recent Developments – U.S. Data Breach Reporting Obligations, Hughes Hubbard & Reed LLP Client
Advisory, June 2022 (co-author)
What the Biden Administration Will Mean for Japanese Companies, Hughes Hubbard & Reed LLP Client Advisory, January 2021 (co-author)
International Arbitration – Potential Advantages for Japanese Companies, AOS/Hughes Hubbard & Reed LLP Webinar, December 16, 2020 (speaker)
Class Certification Denied in Antitrust Lawsuit against Japanese Companies, Hughes Hubbard & Reed LLP Client Advisory, November 2020 (co-author)
International Arbitration: Discovery Strategies, Fronteo/Hughes Hubbard & Reed LLP Webinar, November 19, 2020 (speaker)
U.S. Litigation – How to Prepare, Protect Yourself and Maximize Your Chance of Success, AOS/Hughes Hubbard & Reed LLP Webinar, October 13, 2020 (speaker)
Highlighted Matters
Represented SPAC Isos Acquisition Corp., in its $2.6 billion IPO merger with Bowlero Corp. that took the world’s largest owner and operator of bowling centers public
Represented a major Japanese construction, civil engineering and real estate development company in acquisitions of: (i) a partial ownership interest in a building and redevelopment project in Los Angeles, California; (ii) a controlling stake in a holding company that indirectly owns 98 percent of two office buildings in Boston, Massachusetts; (iii) a partial ownership interest in a newly formed joint venture which will develop a mixed use office and retail building in Washington, D.C.; and (iv) a partial ownership interest in a newly formed joint venture which will develop a 60-story mixed use office, retail and residential building in Atlanta, Georgia
Represented Ajinomoto Co., Inc., a Japanese multinational food and biotechnology corporation, in various collaboration and licensing agreements relating to food additives, among other things
Represented Sumitomo Pharma Co., Ltd. in connection with a licensing agreement with AstraZeneca PLC for pharmaceutical sales in Southeast Asia
